



Bangladesh Association for Child & Adolescent Mental Health (BACAMH)

Executive Council 2024-2025

President

Prof. Dr. Shalahuddin Qusar Biplob

Vice-President

Prof. Dr. Md Mohsin Ali Shah

Immediate Past President

Dr. Helal Uddin Ahmed

Secretary General

Dr. Md Rahanul Islam

Mobile: +8801711587901

Email: rahanul@gmail.com

Joint Secretary

Dr. Shelina Fatema Binte Shahid (PhD)

Dr. Golam Mostafa

Treasurer

Dr. Wasima Rahman

Phone : +8801715011422

Email : wasimapsy@gmail.com

Office Secretary

Dr. A S M Morshed

Academic Secretary

Dr. Nusrat Jahan Tanzilla

Counsellors

Prof. Dr. Md Faruq Alam

Prof. Dr. Md. Nizam Uddin

Prof. Dr. Nahid Mahjabin Morshed

Prof. Dr. Syeda Tabassum Alam

Dr. Sadia Afrin

Dr. Munaim Reza

Dr. Mahabuba Rahman

Md. Belal Hossen

Room no: 1210, D Block, 12th floor
Department of Psychiatry,
Bangabandhu Sheikh Mujib Medical
University (BSMMU)
Shahbag, Dhaka-1000.
Web : www.bacamh.org
Email: bacamh@gmail.com

Ref:

17 April, 2025

To:

The WHO Expert Committee on Selection and Use of Essential Medicines

Subject: Support for Application Reference "A.19 Methylphenidate – Attention Deficit Hyperactivity Disorder"

To Whom It May Concern

I am writing to express my strong support for the inclusion of methylphenidate in the WHO Model List of Essential Medicines, as proposed in application reference A.19 Methylphenidate – Attention Deficit Hyperactivity Disorder.

In Bangladesh, 2% of children suffer from Attention Deficit Hyperactivity Disorder (ADHD), and the availability of methylphenidate remains a significant challenge. Patients are frequently forced to discontinue treatment due to unavailability of the medication, and even in major cities. Furthermore, the high cost of methylphenidate imposes an additional barrier. A single 10 mg immediate-release tablet costs approximately USD 0.14, which is considerably expensive within the context of our national economic conditions.

Due to both limited availability and affordability, psychiatrists are often compelled to prescribe alternative medications which, regrettably, are not as effective as methylphenidate in managing ADHD. As such, ensuring a reliable, affordable, and sustained supply of methylphenidate is of critical importance for the optimal treatment of ADHD in our setting. Several leading child psychiatrist and adult psychiatrist of Bangladesh consented to take initiatives to include methylphenidate in WHO Model List of Essential Medicines and in national list in a scientific seminar followed by general discussion organized by Association of Child and Adolescent Mental Health (BACAMH) attended on 17.04.25.

I sincerely urge the committee and relevant stakeholders to give this matter the utmost consideration, recognizing its significant implications for child and adolescent mental health in low-resource settings like Bangladesh.

Sincerely,

Professor Dr. Shalahuddin Qusar Biplob

President

Bangladesh Association of Child and Adolescent Mental Health (BACAMH)